Investor Relations Home - Achieve Life Sciences

Investors Home

Home 2017-06-16T21:39:52+00:00

Investors Home

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.

Stock Info

Recent Press Releases

Recent News
Apr 22, 2021

SEATTLE, Wash and VANCOUVER, British Columbia, April 22, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Apr 14, 2021

Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, Wash and VANCOUVER,...

Mar 25, 2021

Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline SEATTLE, Wash and...